No”True” Vaccine

There is no true vaccine for RSV, although it’s development is a high research priority. WAVE predicts that a vaccine will soon be established. An “antibody” injection has been manufactured, a “humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitome in the A antigenic site of the F protein of respiratory syncytial virus.” However, adverse reactions can be similar to that of a vaccine.

Five Injections

Medical doctors recommend five consecutive intramuscular injection for infants under 2 years of age, typically administered in RSV “season” which is November through April.

Adverse Reactions and Unknown Effects

Ingredients include the RSV virus proteins, mannitol, glycine, histidine – which are toxic when injected into the human body, especially infants.

According to the company package insert for this product:

Adverse reactions: upper respiratory tract infections, otitis media, fever, rash, diarrhea, vomiting, gastroenteritis and wheezing were commonly found side-effects when studies were performed. Anaphylaxis, dyspnea, cyanosis, respiratory failure, urticaria, pruritis, angioderma, hypotonia, and unresponsiveness were also noted in infants given the RSV “vaccine.”

Carcinogenicity, mutagenesis (chromosomal damage) and reproductive toxicity (impairment of fertility) studies have not been performed.”

“Because clinical trials are conducted under varying conditions, adverse event rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.”

Product package insert:

A very common and relatively benign disease

Almost all kids are infected with RSV at least once by the time they are 2 years old. In adults, it may only produce symptoms of a common cold, such as a stuffy or runny nose, sore throat, mild headache, cough, fever, and a general feeling of being ill. During their first RSV infection, between 25% and 40% of infants and young children have signs or symptoms of bronchiolitis or pneumonia, and 0.5% to 2% require hospitalization. Most children recover from illness in 8 to 15 days. For children with mild disease, no specific treatment is necessary.

Rare Mortality In Infants

In fact a recent study found that more than 78 percent of RSV-associated underlying respiratory and circulatory deaths occurred among people aged 65 and older and, On average, influenza was associated with 3 times as many deaths as RSV.



Respiratory Syncytial Vaccines by Brand